XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

Key facts

Sponsor

XVIVO Perfusion

Principal Investigator

Sarah Lowe

XVIVO Perfusion

Intervention

Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)(device)

Enrollment

60 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2031

Study locations (14)

• UC San Diego Health, La Jolla, California, United States
• Cedars Sinai Medical Center, Los Angeles, California, United States
• University of California Los Angeles, Los Angeles, California, United States
• Stanford University, Stanford, California, United States
• Emory University Hospital, Atlanta, Georgia, United States
• Northwestern Memorial Hospital, Chicago, Illinois, United States
• Washington University - Barnes Jewish Health Hospital, St Louis, Missouri, United States
• University of Nebraska Medical Center, Omaha, Nebraska, United States
• NYU Langone, New York, New York, United States
• Columbia University Medical Center/New York Presbyterian Hospital, New York, New York, United States
• Duke University Medical Center, Durham, North Carolina, United States
• Vanderbilt University Medical Center, Nashville, Tennessee, United States
• University of Texas Southwestern Medical Center, Dallas, Texas, United States
• University of Washington Medical Center, Seattle, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05621291
  A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT06738368
  Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
  University of Washington
• ENROLLING BY INVITATIONNCT07511959
  Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative Dentistry
  Wroclaw Medical University
• RECRUITINGNANCT07191119
  Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
  St. Jude Children's Research Hospital
• RECRUITINGPHASE2NCT07275762
  Y-4 to Treat the Postherpetic Neuralgia
  Neurodawn Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07177183
  Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure
  University Hospital Ostrava
• RECRUITINGNANCT07201974
  Virtual Reality for Post-Stroke Gait Rehabilitation
  McGill University
• ENROLLING BY INVITATIONNCT07515430
  The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia
  Sun Yat-sen University

See all trials for Acute lymphoblastic leukemia →